Active, Not Recruiting
A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy
NCT04666740
- Conditions
- Homologous Recombination Deficiency (HRD), Metastatic Pancreatic Ductal Adenocarcinoma
- Locations
-
- Memorial Sloan Kettering Monmouth (All protocol activities) Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (All protocol activities) Montvale, New Jersey, United States
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities) Commack, New York, United States
- Memorial Sloan Kettering Westchester (All Protocol Activities) Harrison, New York, United States